NCT03792854 Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)
| NCT ID | NCT03792854 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Condition | Anal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2018-12-01 |
| Primary Completion | 2021-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2018-12-01 with a primary completion date of 2021-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer
Eligibility Criteria
Inclusion Criteria: * histologically proven anal cancer without distant metastases * indication for definitive chemoradiation therapy based on multidisciplinary evaluation * age \>=18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * prior systemic therapy with regard to anal cancer * distant metastases * second malignancy
Contact & Investigator
Falk Roeder, MD
PRINCIPAL INVESTIGATOR
Ludwig-Maximilians Universität München
Frequently Asked Questions
Who can join the NCT03792854 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03792854 currently recruiting?
Yes, NCT03792854 is actively recruiting participants. Contact the research team at falk.roeder@t-online.de for enrollment information.
Where is the NCT03792854 trial being conducted?
This trial is being conducted at Munich, Germany.
Who is sponsoring the NCT03792854 clinical trial?
NCT03792854 is sponsored by Ludwig-Maximilians - University of Munich. The principal investigator is Falk Roeder, MD at Ludwig-Maximilians Universität München. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.